Study of Qudexy® XR (topiramate) extended-Release Capsules for use in prophylaxis of migraine headache in adults and adolescents

Trial Profile

Study of Qudexy® XR (topiramate) extended-Release Capsules for use in prophylaxis of migraine headache in adults and adolescents

Planning
Phase of Trial: Phase IV

Latest Information Update: 07 Apr 2017

At a glance

  • Drugs Topiramate (Primary)
  • Indications Migraine
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Apr 2017 New trial record
    • 30 Mar 2017 According to a Upsher-Smith media release, the company has received U.S. Food and Drug Administration (FDA) final approval of two supplemental new drug applications (sNDAs) for Qudexy XR (topiramate) Extended-Release Capsules for use as prophylaxis of migraine headache in adults and adolescents 12 years of age and older.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top